A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System
Clinical trial NCT06385522 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06385522
- Sponsor
- Boston Immune Technologies and Therapeutics
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-08-01
- Primary completion
- 2026-06-01
- Enrollment
- 37
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.